For the third year in a row, Wynnewood’s Lankenau Medical Center has been named one of America’s 50 best hospitals by Healthgrades, writes John George for Philadelphia Business Journal.

The hope is the therapy can effectively target cancerous cells at relatively small doses while minimizing side effects.

The phase 2a LEGION-100 trial seeks to evaluate the safety and effectiveness of the SYNC-T/SV-102 combination therapy for treating metastatic castration-resistant prostate cancer (mCRPC) and to ...

Dr. Stephen E. Lankenau is a sociologist who combines public health concerns and mixed methods to the study of substance use and health outcomes associated with use, including homelessness, HIV/AIDS, ...

Dr. Lankenau is a sociologist who combines public health concerns and ethnographic methods to the study of substance use and health outcomes associated with use, including homelessness, HIV/AIDS, and ...